Evidence map›Paper›PMID 29755657›Full record

ArticleOncotarget2018

Regulatory effect of anti-gp130 functional mAb on IL-6 mediated RANKL and Wnt5a expression through JAK-STAT3 signaling pathway in FLS.

Ping Miao, Xiao Wei Zhou, Ping Wang, Rong Zhao, Ninan Chen, Chao Ying Hu, Xue Hua Chen, Liu Qian, Qi Wen Yu, Ji Ying Zhang and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. The Regulation of Bone Metabolism and Disorders by Wnt Signaling.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Ping MiaoDepartment of Laboratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiao Wei ZhouReproductive Medical Center of Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Ping WangShanghai Jiao Tong University School of Medicine, XinHua Hospital, Shanghai, China.
Rong ZhaoShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ninan ChenShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chao Ying HuShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xue Hua ChenDepartment of Pediatrics, Ruijin Hospital and Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Liu QianShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qi Wen YuShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ji Ying ZhangShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Rong XuShanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Dong Yi HeShanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Lian Bo XiaoShanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China.
Pu LiDepartment of Pediatrics, Ruijin Hospital and Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mason LuMedAbome, Inc, Fremont, CA, USA.
Dong Qing ZhangShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Jiao Tong University · CNShanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine · CNRenji Hospital · CNRuijin Hospital · CNShanghai Xuhui Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the effect on rheumatoid arthritis (RA) of an anti-gp130 monoclonal antibody (mAb) and its mechanism using RA fibroblast-like synoviocytes (FLS) and a collagen antibody-induced arthritis (CAIA) mouse model. We determined the interleukin 6 (IL-6), IL-6 receptor α (IL-6Rα), gp130, receptor activator of nuclear factor κB ligand (RANKL), matrix metalloproteinase 3 (MMP3), TIMP metallopeptidase inhibitor 1 (TIMP1), and Bcl-2 levels in RA and osteoarthritis (OA) serum and synovial fluid. RA FLS were cultured with or without IL-6/IL-6Rα; WNT5A and RANKL levels were detected. We generated an anti-gp130 mAb (M10) with higher affinity and specificity, blocked IL-6 signaling with it, and assessed its effects on the CAIA model,

Indexed as

collagen II antibody-induced arthritisgp130receptor activator of nuclear factor κB ligandrheumatoid arthritisSTAT3

Identifiers

PMID29755657
PMCPMC5945543
OpenAlexW2782104481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.